Dr. Lisa A. Rubinsak, MD

Dr. Rubinsak practices at Arnold Palmer Hospital for Children in Orlando, Florida.

Dr. Rubinsak's NPI, 1093007726, was assigned on May 13, 2011. Dr. Rubinsak graduated from Florida State University College Of Medicine in 2011. Dr. Rubinsak holds Florida license ME157719.

Dr. Rubinsak's primary practice is Arnold Palmer Hospital for Children, at 92 W Miller St, Orlando, FL 32806 in Orange County. The practice phone is (407) 650-5028.

Dr. Rubinsak's primary practice is Arnold Palmer Hospital for Children in Orlando, Florida. Dr. Rubinsak is also affiliated with Orlando Regional Medical Center. The medical group on file is Orlando Health Medical Group. Dmand AI also links Dr. Rubinsak to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rubinsak practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Rubinsak's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Rubinsak is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Rubinsak's licenses on file in 5 states: Florida, Michigan, Virginia, Maryland and Georgia.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Rubinsak treats.

CMS data shows 91 Medicare services from Dr. Rubinsak across 4 procedure codes in 2024, all of them office visits, for 51 Medicare patients. Medicare paid $8,198 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 51 Medicare patients who saw Dr. Rubinsak in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rubinsak's median patient age at 68, with 98% women.

In 2024, Dr. Rubinsak wrote 315 Medicare Part D claims for 75 patients. 78% of them were for generic drugs. CMS names the drug for 182 of them, across 9 drugs with 11 or more claims each, at $587,648 in total drug cost. In 2023, CMS named 165 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Rubinsak for performance year 2024, reported as part of a group. Dr. Rubinsak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rubinsak as offering telehealth. CMS counts 17 procedures of removal of the uterus by Dr. Rubinsak, more than 90% of the clinicians it reports for that procedure.

Dmand AI links 12 papers to Dr. Rubinsak, published from 2018 to 2022. 2018 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms, Menopause and Uterine Cervical Neoplasms. Dr. Rubinsak has published most often in Front Oncol. Dr. Rubinsak's most frequent co-authors are Sarah M. Temkin, MD, Michelle F. Benoit, MD and Uma Chandavarkar, MD.

CMS Open Payments shows 24 general payments to Dr. Rubinsak from 13 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $283.

Dr. Rubinsak graduated from Florida State University College Of Medicine in 2011.

Dr. Rubinsak is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.